Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Atara Biotherapeutics (ATRA) Gross Margin (2022 - 2026)

Atara Biotherapeutics filings provide 5 years of Gross Margin readings, the most recent being 75.97% for Q1 2026.

  • On a quarterly basis, Gross Margin fell 321.0% to 75.97% in Q1 2026 year-over-year; TTM through Mar 2026 was 96.12%, a 1588.0% increase, with the full-year FY2025 number at 82.44%, down 127.0% from a year prior.
  • Gross Margin hit 75.97% in Q1 2026 for Atara Biotherapeutics, down from 93.48% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 100.0% in Q1 2022 to a low of 265.07% in Q2 2023.
  • Median Gross Margin over the past 5 years was 83.11% (2024), compared with a mean of 56.83%.
  • Biggest five-year swings in Gross Margin: crashed -36507bps in 2023 and later surged 34891bps in 2024.
  • Atara Biotherapeutics' Gross Margin stood at 100.0% in 2022, then crashed by -65bps to 35.19% in 2023, then surged by 125bps to 79.25% in 2024, then rose by 18bps to 93.48% in 2025, then dropped by -19bps to 75.97% in 2026.
  • The last three reported values for Gross Margin were 75.97% (Q1 2026), 93.48% (Q4 2025), and 96.67% (Q3 2025) per Business Quant data.